Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. ($JANX) announced an update on their ongoing clinical study. Janux Therapeutics, Inc. (JANX) is running a Phase 1 study ca...

Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX

Janux Therapeutics, Inc. ($JANX) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1 Open-Label, Multicenter Study of...

Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play

Analysts are intrested in these 5 stocks: ( ($EAT) ), ( ($WHR) ), ( ($QTTB) ), ( ($PHM) ) and ( ($JANX) ). Here is a breakdown of their recent


	A	B	C	D
1	Symbol	Price	Change	Volume
2	JANX	$16.59	-1.60%	2.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JANX	$16.59	-1.6%	2.45M
3
4
5
6

JANX

Get Janux Therapeutics, Inc. Data in Excel

Get Janux Therapeutics, Inc. Data in Excel